To increase the competitiveness of pharmaceutical enterprises, China and the United States join hands to help new drugs go global

[China Pharmaceutical network industry trends] on March 10, led by Professor Qin Shukui and Professor Li Jin, leaders of China's clinical oncology research, and jointly sponsored by 37 professors from 33 hospitals across the country, China Oriental cancer clinical research cooperation organization was officially established in Shanghai Oriental Hospital It is reported that the establishment of the center will also provide patients with convenient access to international clinical research new drugs and opportunities to participate in international drug clinical trials, so as to promote the clinical diagnosis and treatment of tumors (to increase the competitiveness of pharmaceutical companies, China and the United States will work together to help new drugs go global Photo source: Baidu photo) it is understood that the organization will work together with the world's largest phase I clinical research center, U.S Shida company (Shanghai) to establish phase I clinical research center, promote the listing of domestic drugs, help new drugs go global, and increase the international competitiveness of Chinese pharmaceutical companies Before any new drug is widely used in clinic, it must be tested on animals to prove that the drug is safe and effective; then a dose or a course of tolerance test should be carried out in healthy volunteers to prove that the human body can tolerate and give the safe dose that can be used in clinic in the future, and then the test should be carried out in patients The so-called drug clinical trial refers to the drug research carried out on patients or volunteers to determine whether the test drug is effective and safe Phase I clinical trial is mainly to study the tolerance of people to new drugs, and put forward a preliminary, safe and effective drug delivery scheme to guide the next phase of clinical trial According to reports, the research and development of new drugs has always been a hot area of tumor research To carry out large-scale multi center clinical trials is the key link for new drugs to obtain evidence-based evidence and eventually enter clinical application Li Jin, director of cancer medicine department of Shanghai Oriental Hospital, said in an interview on the same day that at present, there are very few cancer drugs developed in China, especially the original drugs The development speed of biopharmaceutical industry is not commensurate with the influence of China's economy in the world In his opinion, the reason is that there is still a certain gap between China's clinical research ability, influence and level with the rest of the world In fact, at present, a large number of Chinese pharmaceutical enterprises need high-quality platform for clinical trials At present, there are few active phase I clinical trial centers in China Five provinces and one city in East China are developed areas of China's economy, and there are many national pharmaceutical enterprises Shanghai is the leader of new drug research and development, and some large-scale manufacturing enterprises are mainly concentrated in Jiangsu and Shandong The establishment of China Oriental cancer clinical research cooperation organization in Shanghai will facilitate the cooperation between experts and pharmaceutical companies, and promote the research and development of clinical cancer drugs in China Start (Shanghai), the partner of phase I clinical research center established on that day, is headquartered in San Antonio, Texas, USA It is currently the world's largest phase I research center for antitumor drugs Every year, more than 650 new cancer patients participate in phase I clinical trials at start According to reports, phase I clinical research center is expected to open 20 beds According to the operation, 20 beds may be expanded for healthy subjects to meet the needs of multiple research The cooperative company will provide all data platforms and personnel training For the clinical research conducted in phase I clinical research center, all the test data will be backed up in the United States, so that the phase I trials in China and the United States can share the safety data At the same time, these data should meet the clinical requirements of new drugs in the United States Li said that this laid a solid foundation for Chinese enterprises to step out.